Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study

Alex R. Chang, Michael Evans, Christina Yule, Larissa Bohn, Amanda Young, Meredith Lewis, Elisabeth Graboski, Bethany Gerdy, William Ehmann, Jonathan Brady, Leah Lawrence, Natacha Antunes, Jamie Green, Susan Snyder, H. Lester Kirchner, Morgan Grams, Robert Perkins

Research output: Contribution to journalArticle

Abstract

Background: Measurement of albuminuria to stratify risk in chronic kidney disease (CKD) is not done universally in the primary care setting despite recommendation in KDIGO (Kidney Disease Improving Global Outcomes) guidelines. Pharmacist medication therapy management (MTM) may be helpful in improving CKD risk stratification and management. Methods: We conducted a pragmatic, cluster-randomized trial using seven primary care clinic sites in the Geisinger Health System to evaluate the feasibility of pharmacist MTM in patients with estimated glomerular filtration rate (eGFR) 45-59 ml/min/1.73 m2 and uncontrolled blood pressure (≥150/85 mmHg). In the three pharmacist MTM sites, pharmacists were instructed to follow a protocol aimed to improve adherence to KDIGO guidelines on testing for proteinuria and lipids, and statin and blood pressure medical therapy. In the four control clinics, patients received usual care. The primary outcome was proteinuria screening over a follow-up of 1 year. A telephone survey was administered to physicians, pharmacists, and patients in the pharmacist MTM arm at the end of the trial. Results: Baseline characteristics were similar between pharmacist MTM (n = 24) and control (n = 23) patients, although pharmacist MTM patients tended to be younger (64 vs. 71 y; p = 0.06) and less likely to have diabetes (17 % vs. 35 %; p = 0.2) or baseline proteinuria screening (41.7 % vs. 60.9 %, p = 0.2). Mean eGFR was 54 ml/min/1.73 m2 in both groups. The pharmacist MTM intervention did not significantly improve total proteinuria screening at the population level (OR 2.6, 95 % CI: 0.5-14.0; p = 0.3). However, it tended to increase screening of previously unscreened patients (78.6 % in the pharmacist MTM group compared to 33.3 % in the control group; OR 7.3, 95 % CI: 0.96-56.3; p = 0.05). In general, the intervention was well-received by patients, pharmacists, and providers, who agreed that pharmacists could play an important role in CKD management. A few patients contacted the research team to express anxiety about having a CKD diagnosis without prior knowledge. Conclusions: Pharmacist MTM may be useful in improving risk stratification and management of CKD in the primary care setting, although implementation requires ongoing education and multidisciplinary collaboration and careful communication regarding CKD diagnosis. Future studies are needed to establish the effectiveness of pharmacist MTM on slowing CKD progression and improvement in cardiovascular outcomes. Trial registration: ClinicalTrials.gov, NCT02208674 Registered August 1, 2014, first patient enrolled September 30, 2014

Original languageEnglish (US)
Article number168
Pages (from-to)1-9
Number of pages9
JournalBMC nephrology
Volume17
Issue number1
DOIs
StatePublished - Nov 8 2016

Keywords

  • Albuminuria
  • Chronic kidney disease
  • KDIGO guidelines
  • Pharmacist medication therapy management
  • Proteinuria
  • Screening

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study'. Together they form a unique fingerprint.

  • Cite this

    Chang, A. R., Evans, M., Yule, C., Bohn, L., Young, A., Lewis, M., Graboski, E., Gerdy, B., Ehmann, W., Brady, J., Lawrence, L., Antunes, N., Green, J., Snyder, S., Kirchner, H. L., Grams, M., & Perkins, R. (2016). Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study. BMC nephrology, 17(1), 1-9. [168]. https://doi.org/10.1186/s12882-016-0383-7